References
- 1. Benza, R.L., et al., An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest, 2012. 142(2): p. 448-456.10.1378/chest.11-146022281797
- 2. Escribano-Subias, P., et al., Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J, 2012. 40(3): p. 596-603.10.1183/09031936.0010121122362843
- 3. Jing, Z.C., et al., Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest, 2007. 132(2): p. 373-9.10.1378/chest.06-291317400671
- 4. Tamura, Y., et al., Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. Circ J, 2017. 82(1): p. 275-282.10.1253/circj.CJ-17-013928747612
- 5. Batton, K.A., et al., Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease. Biol Sex Differ, 2018. 9(1): p. 15.10.1186/s13293-018-0176-8590745029669571
- 6. Chung, L., et al., Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest, 2014. 146(6): p. 1494-1504.10.1378/chest.13-3014425161324992469
- 7. Tofovic, S.P., et al., Estradiol metabolites attenuate monocrotaline-induced pulmonary hyper-tension in rats. J Cardiovasc Pharmacol, 2005. 46(4): p. 430-7.10.1097/01.fjc.0000175878.32920.1716160593
- 8. Tofovic, S.P., et al., 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol, 2006. 45(6): p. 358-67.10.1016/j.vph.2006.05.00716872912
- 9. Tofovic, S.P., et al., 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol, 2009. 51(2-3): p. 190-7.10.1016/j.vph.2009.06.002276030019540933
- 10. Tofovic, S.P., Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol, 2010. 56(6): p. 696-708.10.1097/FJC.0b013e3181f9ea8d302783920881610
- 11. Austin, E.D., et al., Gender, sex hormones and pulmonary hypertension. Pulm Circ, 2013. 3(2): p. 294-314.10.4103/2045-8932.114756375782424015330
- 12. Tofovic, S.P. and E.K. Jackson, Estradiol Metabolism: Crossroads in Pulmonary Arterial Hyper-tension. Int J Mol Sci, 2019. 21(1).10.3390/ijms21010116698232731877978
- 13. Austin, E.D., et al., Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J, 2009. 34(5): p. 1093-9.10.1183/09031936.00010409374212419357154
- 14. Kawut, S.M., et al., Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest, 2009. 135(3): p. 752-759.10.1378/chest.08-1758283478518849396
- 15. Kawut, S.M., et al., Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med, 2017. 195(3): p. 360-368.10.1164/rccm.201605-1024OC
- 16. Ventetuolo, C.E., et al., Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. Am J Respir Crit Care Med, 2016. 193(10): p. 1168-75.10.1164/rccm.201509-1785OC487266526651504
- 17. Ventetuolo, C.E., et al., Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J, 2016. 47(2): p. 553-63.10.1183/13993003.01083-2015483113526647441
- 18. Tofovic, S.P. and E.K. Jackson, Complexities of oestradiol pharmacology in pulmonary arterial hypertension. Eur Respir J, 2013. 41(6): p. 1465-6.10.1183/09031936.0016491223728411
- 19. Tofovic, S.P. and E.K. Jackson, Estrogens in Men: Another Layer of Complexity of Estradiol Metabolism in Pulmonary Hypertension. Am J Respir Crit Care Med, 2016. 193(10): p. 1087-90.10.1164/rccm.201512-2541ED487267327174480
- 20. Tofovic, S.P.a.J., E.K., 2-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier, in Pulmonary Circulation and Ventilation. 2019, IntechOpen.10.5772/intechopen.86812
- 21. Kay, J.M., Effect of intermittent normoxia on chronic hypoxic pulmonary hypertension, right ventricular hypertrophy, and polycythemia in rats. Am Rev Respir Dis, 1980. 121(6): p. 993-1001.
- 22. Swigart, R.H., Polycythemia and Right Ventricular Hypertrophy. Circ Res, 1965. 17: p. 30-8.10.1161/01.RES.17.1.3014302550
- 23. Naeije, R. and C. Dedobbeleer, Pulmonary hypertension and the right ventricle in hypoxia. Exp Physiol, 2013. 98(8): p. 1247-56.10.1113/expphysiol.2012.06911223625956
- 24. Tofovic SP, Z.X., Jones T,Jackson EK, Petrusevska G., 2-Methoxyestradiol attenuates the development and retards the progression of chronic hypoxia-induced pulmonary hypertension in rats. Circulation, 2005. 112: p. 98-99.
- 25. Hao, S., et al., 2-Methoxyestradiol attenuates chronic-intermittent-hypoxia-induced pulmonary hypertension through regulating microRNA-223. J Cell Physiol, 2019. 234(5): p. 6324-6335.10.1002/jcp.2736330246291
- 26. Docherty, C.K., M. Nilsen, and M.R. MacLean, Influence of 2-Methoxyestradiol and Sex on Hypoxia-Induced Pulmonary Hypertension and Hypoxia-Inducible Factor-1-alpha. J Am Heart Assoc, 2019. 8(5): p. e011628.10.1161/JAHA.118.011628647494030819028
- 27. Tofovic, S.P., T. Jones, and G. Petrusevska, Dose-dependent therapeutic effects of 2-Methoxyestradiol on Monocrotaline-Induced pulmonary hypertension and vascular remodelling. Prilozi, 2010. 31(1): p. 279-95.
- 28. Tofovic, S.P., et al., Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling. J Cardiovasc Pharmacol, 2010. 56(5): p. 475-83.10.1097/FJC.0b013e3181f215e720881615
- 29. Havill, A.M., et al., alpha-Naphthylthiourea produces dose-dependent lung vascular injury in sheep. Am J Physiol, 1982. 243(4): p. H505-11.10.1152/ajpheart.1982.243.4.H5056812437
- 30. Hesse, F.E. and C.G. Loosli, The lining of the alveoli in mice, rats, dogs, and frogs following acute pulmonary edema produced by ANTU poisoning. Anat Rec, 1949. 105(2): p. 299-323, incl 6 pl.10.1002/ar.109105020715398723
- 31. Michel, R.P., Lung microvascular permeability to dextran in alpha-naphthylthiourea-induced edema. Sites of filtration, patterns of accumulation, and effects of fixation. Am J Pathol, 1985. 119(3): p. 474-84.
- 32. Verenich, S. and P.M. Gerk, Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm, 2010. 7(6): p. 2030-9.10.1021/mp100190f305989920831190
- 33. Berg, D., R. Sonsalla, and E. Kuss, Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Co-penh), 1983. 103(2): p. 282-8.10.1530/acta.0.10302826858558
- 34. Tofovic SP, Jackson EK, Piche C, Pharmacokinetics and safety of a subcutaneously injected long-acting formulation of 2-methoxyestradiol(2ME) in healthy volunteers. Basic & Clinical Pharmacology & Toxicology, 2009. 105: p. 107.
- 35. Ba, M. and Y. Duan, Advance of 2-methoxyestradiol as a promising anticancer agent for cancer therapy. Future Med Chem, 2020. 12(4): p. 273-275.10.4155/fmc-2019-025831983223
- 36. Kumar, B.S., et al., Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug. Steroids, 2016. 110: p. 9-34.10.1016/j.steroids.2016.03.01727020471